natgillin/translations-raw huggingface dataset:
250 mg/25 mg powder for solution for injection or infusion in
250 mg/25 mg prašek za raztopino za injiciranje ali infundiranje Nemčija - Augmentan
Adults and children  40 kg CrCl: 10-30 ml/min 500 mg/125 mg twice daily CrCl < 10 ml /min
Odrasli in otroci  40 kg CrCl 10-30 ml/min
Formulation
Oblika
Augmentin 250 mg/125 mg dispersible tablets are not recommended in children < 40 kg. 125 mg/62.5 mg/5 ml powder for oral suspension
250 mg/125 mg disperzibilne tablete Augmentin 250 mg/125 mg disperzibilne tablete niso priporočljive za otroke < 40 kg.
Augmentin and associated names (see Annex I) 500 mg/100 mg powder for solution for injection or infusion [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 500 mg/100 mg prašek za raztopino za injiciranje ali infundiranje [glejte Dodatek I - izpolni država članica]] amoksicilin/klavulanska kislina
• inflammation of
• bruhanje,
Augmentin and associated names (see Annex I) 125 mg/31.25 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 125 mg/31,25 mg/ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
Augmentin and associated names (see Annex I) 125 mg/62.5 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 125 mg/62,5 mg/ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
Augmentin and associated names (see Annex I) 500 mg/50 mg powder for solution for injection or infusion [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 500 mg/50 mg prašek za raztopino za injiciranje ali infundiranje [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
2000 mg/200 mg powder for solution for infusion This medicinal product contains 125.9 mg (5.5 mmol) of sodium per per vial or bottle.
2000 mg/200 mg prašek za raztopino za infundiranje To zdravilo vsebuje 39,3 mg (1,0 mmol) kalija na vialo ali stekleničko.
NAME OF THE MEDICINAL PRODUCT Augmentin and associated names (see Annex I) 875 mg/125 mg powder for oral suspension [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 875 mg/125 mg prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
250 m 1 g/3 .25 mg powder for oral suspension in sachets Franc A e - ugmentin
250 mg/31,25 mg prašek za peroralno suspenzijo v vrečkah Francija - Augmentin
The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (250 mg/125 mg tablets three times daily) was administered in the fasting state to groups of healthy volunteers are presented below.
Spodaj so predstavljeni farmakokinetični rezultati študije, v kateri so amoksicilin/klavulansko kislino (250 mg/125 mg tablete) na tešče uporabili v skupinah zdravih prostovoljcev.
This should be considered if you are on a controlled sodiu m diet.
Če ste na dieti z nadzorovanim vnosom natrija, morate to upoštevati.
Lot
AUC
com hese may affect up to 1 in 100 people ncommon side effects that may show up in blood tests:
če opazite katerega od teh simptomov, se morate nujno posvetovati z zdravnikom Redki neželeni učinki, ki se lahko pokažejo na preiskavah krvi:
If you forget to give your child a dose, give it as soon as y child the next dose too soon, but wait about 4 hour
Če ste otroku pozabili dati odmerek zdravila, mu ga dajte, čim se spomnite.
Augmentin and associated names (see Annex I) 250 mg/62.5 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 250 mg/62,5 mg/ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] {Name and address}
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET {DD mesec LLLL} [glejte Dodatek I - izpolni država članica]
Augmentin 125 mg/62.5 mg/5 ml powder for oral suspension contains 2.5 mg of aspartame (E951) per ml, a source of phenylalanine.
125 mg/62,5 mg/5 ml prašek za peroralno suspenzijo Zdravilo Augmentin 125 mg/62,5 mg/5 ml prašek za peroralno suspenzijo vsebuje na 1 ml 2,5 mg aspartama (E951), ki je vir fenilalanina.
• Community acquired pneumonia.
• pljučnica, dobljena v domačem okolju.
WHAT IT IS USED FOR
Uporabno do: {MM LLLL}
If your child still feels unwell they doctor.
Če se še vedno ne počutite dobro, ponovno obiščite zdravnika.
If you forget to give your child a dose, give it as so child the next dose too soon, but wait about 4 hours before giving the next dose.
Naslednjega odmerka mu ne smete dati prezgodaj, temveč počakajte približno 4 ure, preden vzame naslednji odmerek.
Augmentin and associated names (see Annex I) 125 mg/31.25 mg powder for oral suspension [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 125 mg/31,25 mg prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
PHARMACEUTICAL FORM Powder for oral suspension.
FARMACEVTSKA OBLIKA prašek za peroralno suspenzijo [Izpolni država članica]
Intermediate
Uporabljeno
Augmentin and associated names (see Annex I) 500 mg/62.5 mg powder for oral suspension [See Annex I - To be completed nationally]
Augmentin in povezana imena (glejte Dodatek I) 500 mg/62,5 mg prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
{MM/YYYY}.
• prebavil,
If y ur child stops taking Augmentin
Otrok naj neha jemati zdravilo Augmentin.
gm rks.
Cmax tmax
6 July 2012
6. julij 2012
This change was to be recognised in the Netherlands and all other
To spremembo bi bilo treba odobriti na Nizozemskem in v vseh drugih zadevnih državah članicah.
Outcome of a procedure under Article 6(12) of Regulation (EC) 1084/2003 as amended
Izid postopka iz člena 6 (12) Uredbe 1084/2003/ES, kakor je bila spremenjena.
Because the Member States were not able to reach an agreement on this new indication, on 28 and 29 June 2011 the Italian and Swedish medicines regulatory agencies referred the matter to the CHMP for arbitration.
Ker se države članice niso uspele sporazumeti o tej novi indikaciji, sta italijanska in švedska regulativna agencija za zdravila 28. in 29. junija 2011 zadevo poslali odboru CHMP v arbitražo.
The Committee reviewed the two main studies presented by the company to support the new indication.
Odbor je pregledal dve glavni študiji, ki jih je za podporo nove indikacije predložila družba Bayer B.V.
The grounds for the referral were concerns over whether the medicines' benefits in the combined indication outweighed their risks, particularly the risk of venous thromboembolism (VTE, formation of blood clots in the veins).
Razlog za napotitveni postopek so bili pomisleki glede tega, ali so koristi zdravil pri kombinirani indikaciji večje od tveganj, predvsem od tveganja za vensko trombembolijo (VTE, tvorbo krvnih strdkov v venah).
They contain two active substances, ethinylestradiol and drospirenone, which are derived from natural hormones produced in the ovaries: ethinylestradiol is derived from oestrogen and drospirenone is derived from progesterone.
Vsebujeta dve zdravilni učinkovini, etinilestradiol in drospirenon, pridobljeni iz naravnih hormonov, ki jih tvorijo jajčniki: etinilestradiol je pridobljen iz estrogena in drospirenon iz progesterona.
The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to consider a proposed change to the marketing authorisations for these medicines to include a new indication for the treatment of moderate acne in women seeking oral contraception.
Odbor za zdravila za humano uporabo (CHMP) pri Evropski agenciji za zdravila je bil naprošen, naj pregleda predlagano spremembo dovoljenja za promet s tema zdraviloma, ki vključuje novo indikacijo za zdravljenje zmernih aken pri ženskah, ki želijo uporabljati peroralno kontracepcijo.
1 Yaz is authorised in all EU Member States except Hungary, and Ethinylestradiol-Drospirenone 24+4 is authorised in the following Member States: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Malta, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom.
Zdravilo Yaz je odobreno v vseh državah članicah EU, razen na Madžarskem, zdravilo Ethinylestradiol-Drospirenone 24+4 pa je odobreno v naslednjih državah članicah: v Avstriji, Bolgariji, na Cipru, Češkem, Danskem, Finskem, v Franciji,
The Committee concluded that the change to the marketing authorisations cannot be granted.
Odbor je sklenil, da spremembe dovoljenja za promet z zdraviloma ni mogoče odobriti.
Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 are authorised in several Member States of the European Union (EU)1 under a mutual recognition procedure on the basis of an initial authorisation granted by the Netherlands.
Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 sta po postopku medsebojnega priznavanja na podlagi prvotnega dovoljenja, odobrenega na Nizozemskem, odobreni v več državah članicah Evropske unije (EU)1.
The Committee concluded that the variation to the marketing authorisations for these medicines cannot be approved.
Odbor je sklenil, da spremembe dovoljenja za promet s tema zdraviloma ni mogoče odobriti.
Therefore, based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP considered that the benefits of Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 did not outweigh their risks in the proposed new indication.
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave znotraj odbora je odbor CHMP sklenil, da koristi zdravil Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 pri na novo predlagani indikaciji niso večje od tveganj, povezanih z njima.
The European Commission issued the decisions on 3 July 2012 (Yaz 24+4) and 6 July 2012 (Ethinylestradiol-Drospirenone 24+4).
Evropska komisija je sklepa izdala 3. julija 2012 (Yaz 24+4) in 6. julija 2012 (EthinylestradiolDrospirenone 24+4).
Women not seeking contraception would therefore be unnecessarily exposed to the risks of Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 when alternative acne treatments are available.
Ženske, ki ne želijo prejemati peroralne kontracepcije, bi bile tako po nepotrebnem izpostavljene tveganjem pri zdravilih Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4, kadar so na voljo alternativne oblike zdravljenja aken.
Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 work by changing the body's hormonal balance to prevent ovulation, by altering the mucus in the cervix (neck of the womb) and by thinning the endometrium (the lining of the womb).
Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 delujeta tako, da spremenita hormonsko ravnovesje v telesu, saj spremenita sluznico v materničnem vratu in stanjšata endometrij (maternično sluznico), kar prepreči ovulacijo.
The company applied for a change to the marketing authorisations of these medicines to extend their use to include the ‘treatment of moderate acne vulgaris only in women seeking oral contraception'.
zdraviloma, da bi razširila njuno uporabo tako, da bi vključila indikacijo „zdravljenje navadnih zmernih aken samo pri ženskah, ki želijo prejemati peroralno kontracepcijo“.
Questions and answers on Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets) EMA/550781/2012
Vprašanja in odgovori za zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 (etinilestradiol/drospirenon, 0,02 mg/3 mg tablete) EMA/257547/2012
On 19 April 2012, the European Medicines Agency completed an arbitration procedure for Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4.
Evropska agencija za zdravila je 19. aprila 2012 končala postopek arbitraže za zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4.
The Committee also considered the known risks with Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4, including VTE.
Odbor je prav tako upošteval znana tveganja, povezana z zdraviloma Yaz 24+4 in EthinylestradiolDrospirenone 24+4, vključno z VTE.
Questions and answers on Yaz 24+4 and EthinylestradiolDrospirenone 24+4 (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets)
Vprašanja in odgovori za zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 (etinilestradiol/drospirenon, 0,02 mg/3 mg tablete)
The CHMP noted the overall effectiveness of Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 compared with placebo in the treatment of acne.
Odbor CHMP je upošteval splošno učinkovitost zdravil Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 pri zdravljenju aken v primerjavi s placebom.
Why were Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 reviewed?
Zakaj sta bili zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 pregledani?
Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 are combined contraceptive pills.
Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 sta kombinirani kontracepcijski tableti.
Since acne is a common problem in young women, the CHMP was concerned that the measures proposed by the company to ensure that these medicines would be used to treat acne only in women seeking oral contraception were not sufficient.
Ker so akne pogosta težava pri mladih ženskah, je odbor CHMP menil, da ukrepi, ki jih je družba Bayer B.V.
The company that markets Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 is Bayer B.V.
Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 trži družba Bayer B.V.
What are Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4?
Kaj sta zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4?
This product information is the outcome of the referral procedure to which this Commission decision relates.
Te informacije o zdravilu so nastale na podlagi napotitvenega postopka, na katerega se nanaša ta sklep Komisije.
The valid product information is the final version achieved during the Coordination group procedure.
Veljavne informacije o zdravilu predstavljajo dokončno različico, ki je bila sprejeta v okviru postopka koordinacijske skupine.
• if you gave birth less than a few weeks ago.
• če ste pred manj kot nekaj tedni rodili.
Seek urgent medical attention
Nujno medicinsko pomoč poiščite
• Sensitivity to sunlight.
• občutljivost na sončno svetlobo.
• Wait until you get your menstrual period.
• Počakajte, da dobite menstruacijo.
There was no significant effect of cool water on these parameters.
Hladna voda ni pomembno vplivala na te parametre.
• This usually stops after the first few cycles.
• Te ponavadi prenehajo po prvih nekaj ciklih.
Are you experiencing any of these signs?
Ali imate katerega od teh znakov?
Women should be advised not to smoke if they wish to use a CHC.
Ženskam je treba svetovati, da naj ne kadijo, če želijo uporabljati CHC.
The frequency and nature of examinations should be based on established practice guidelines and be adapted to the individual woman.
Pogostnost in naravo pregledov je treba določiti na temelju uveljavljenih smernic za prakso in ju prilagoditi posamezni ženski.
In both cases, the number of VTEs per year is fewer than the number expected in women during pregnancy or in the postpartum period.
V obeh primerih je število VTE na leto manjše od števila, ki se pričakuje pri ženskah med nosečnostjo ali v obdobju po porodu.
The net effect of these changes may be clinically relevant in some cases.
Končen učinek teh sprememb je lahko v nekaterih primerih klinično pomemben.
Always use condoms to protect yourself from these diseases.
Za zaščito pred temi boleznimi vedno uporabljajte kondome.
It is important to tell your doctor if any of these conditions apply to you, even if you are unsure.
Pomembno je, da zdravniku poveste, ali katero od teh stanj velja za vas, tudi če niste prepričani.
Do not put on a patch this week.
ta teden obliža ne uporabljajte.
Recovery from blood clots is not always complete.
Okrevanje od krvnih strdkov ni vedno popolno.
VTE may be fatal in 1-2% of cases.
VTE se v 1-2% primerov lahko konča s smrtjo.
However, this may be due to other causes including sexually-transmitted disease.
To je lahko posledica drugih dejavnikov, vključno s spolno prenosljivimi boleznimi.
• Problems sleeping (insomnia)
• težave s spanjem (nespečnost)
It is used to prevent pregnancy.
Uporablja se za preprečevanje nosečnosti.
The following interactions have been reported in the literature.
Spodnje interakcije so bile navedene v literaturi.
Symptoms most commonly occur in one eye:
Simptomi, ki se najpogosteje pojavijo na enem očesu:
• Do not try to put a patch back on if:
• Obliža ne poskušajte ponovno namestiti, če:
• sudden trouble seeing in one or both eyes;
• nenadne težave z vidom na enem ali obeh očesih;
Number of VTE events per 10,000 women in one year
Število dogodkov VTE na 10.000 žensk v enem letu
Particularly important to consider if other risk factors also present.
Zlasti pomembno je, da se upošteva, če obstajajo tudi drugi dejavniki tveganja.
The safety and efficacy has been established in women aged 18 to 45 years.
Njegovo varnost in učinkovitost so dokazali pri ženskah med 18. in 45. letom starosti.
For more than 2 days (48 hours or more):
več kot 2 dneva (48 ur ali več):
Particularly important in women with additional risk factors.
To je pomembno zlasti za ženske z dodatnimi dejavniki tveganja
Change day adjustment
Prilagajanje dneva zamenjave
Used transdermal patches should be discarded carefully in accordance with the instructions given in section 6.6.
Uporabljene transdermalne obliže moramo zavreči previdno, v skladu z navodili iz poglavja 6.6.
Clinical efficacy and safety Pearl Indices (see table):
Klinična učinkovitost in varnost Pearlov indeks (glejte preglednico):
• Talk to your doctor.
• Posvetujte se s svojim zdravnikom.
How many patches to use
Koliko obližev je treba uporabiti
• The patch is designed to stay in place during these types of activities.
• Obliž je oblikovan tako, da ostane na mestu tudi v času takšnih aktivnosti.
Safety was evaluated in 3,322 sexually active women who participated in three Phase III clinical trials, which were designed to evaluate contraceptive efficacy.
Varnost so ocenjevali pri 3.322 spolno aktivnih ženskah, vključenih v klinične študije faze III, v katerih so ocenjevali učinkovitost kontraceptiva.
Chloasma is often not fully reversible.
Kloazma pogosto ni popolnoma reverzibilna.
• if you have just given birth you are at an increased risk of blood clots.
• če ste pravkar rodili, obstaja pri vas povečano tveganje za krvne strdke.
Frequency MedDRA convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Navedba pogostnosti neželenih učinkov po MedDRA: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (<1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
If you have more than one of these conditions or if any of them are particularly severe the risk of developing a blood clot may be increased even more.
Če imate več kot eno od teh stanj ali če je katero od njih posebno resno, se lahko tveganje za nastanek krvnega strdka še bolj poveča.
• Week 4:
• 4. teden:
• Keep using the patches even if you do not have sex very often.
• Ne prenehajte uporabljati obližev, tudi če nimate pogostih spolnih odnosov.
All combined birth control pills have risks, which may lead to disability or death.
Vse kombinirane kontracepcijske tablete prinašajo tveganje, ki lahko vodi v invalidnost ali smrt.
Try not to touch the sticky surface.
Pazite, da se ne dotaknete lepljive površine.
For this reason, a medical opinion on irregular blood loss will only be useful after an adjustment period of approximately three cycles.
Zdravniško mnenje o nenormalni krvavitvi bo zato smotrno šele po obdobju prilagajanja, ki traja približno 3 cikle.
Before you start using EVRA you should read the information on blood clots in section 2.
Preden začnete uporabljati obliž EVRA, morate prebrati informacije o krvnih strdkih v poglavju 2.
Other products such as EVRA may have up to twice this level of risk.
Pri drugih zdravilih, kot je zdravilo EVRA, je lahko raven tega tveganja do dvakrat večja.
These findings suggest that clinical efficacy would be maintained even if a scheduled change is missed for as long as 2 full days.
Te ugotovitve kažejo, da bi se klinična učinkovitost ohranila, tudi če bi ženska načrtovano zamenjavo zamudila za 2 dni.
Combined hormonal contraceptives and cancer
Kombinirani hormonski kontraceptivi in rak
Below 90 kg there was no association between body weight and pregnancy.
Pri ženskah z manj kot 90 kg ni bilo povezave med telesno maso in nosečnostjo.
The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.
Tveganje je odvisno od vašega naravnega tveganja za VTE in vrste kombiniranega hormonskega kontraceptiva, ki ga jemljete.
• Take it off as soon as you remember.
• odstranite ga, takoj ko se spomnite.
Arterial thromboembolic events may be fatal.
Dogodki arterijske trombembolije so lahko smrtni.
Changes generally remain within the normal laboratory range.
Spremembe ponavadi ostanejo znotraj meja referenčnih vrednosti.
If you are unable to stop smoking and are older than 35 your doctor may advise you to use a different type of contraceptive;
Če ne morete prenehati kaditi in ste starejši kot 35 let, vam lahko zdravnik svetuje, da uporabljate drugo vrsto kontraceptiva;
Non-hormonal causes should be considered and, if necessary, adequate diagnostic measures taken to rule out organic disease or pregnancy.
Proučiti moramo nehormonske vzroke in, če je potrebno, uvesti ustrezne diagnostične teste, s katerimi izključimo organsko bolezen ali nosečnost.
Therefore, the use of EVRA is not to be recommended until the breast-feeding mother has completely weaned her child.
Zato uporabe obližev EVRA ne priporočamo, dokler mati popolnoma ne preneha z dojenjem.
Do not use this medicine after the expiry date, which is stated on the label after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake “EXP”.
Your doctor may need to adjust the dose of the other medicine.
Zdravnik vam bo morda moral prilagoditi odmerek drugega zdravila.
Protect your skin from sunlight or ultraviolet radiation.
Kožo zaščitite pred sončno svetlobo ali ultravijoličnim sevanjem.
Risk of developing a blood clot in a year
Tveganje za razvoj krvnega strdka v enem letu
• sudden confusion, trouble speaking or understanding;
• nenadna zmedenost, težave z govorjenjem ali razumevanjem;
For more detailed information on the different risks from taking combined hormonal contraceptives please see section 2 “What you need to know before you use EVRA”.
Za podrobnejše informacije o različnih tveganjih zaradi jemanja kombiniranih hormonskih kontraceptivov glejte poglavje 2 "Kaj morate vedeti, preden boste uporabili zdravilo EVRA".
• Never put the patch on your breasts.
• Obliža nikoli ne namestite na prsi.
Sometimes the symptoms of stroke can be brief with an almost immediate and full recovery, but you should still seek urgent medical attention as you may be at risk of another stroke.
Včasih so lahko simptomi možganske kapi kratkotrajni s skoraj takojšnjim in popolnim okrevanjem, vendar morate kljub temu poiskati zdravniško pomoč, saj obstaja tveganje za ponovno možgansko kap.
Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.
Ženskam je treba svetovati, naj pri spremembi razpoloženja in znakih depresije, vključno kmalu po začetku zdravljenja, stopijo v stik z zdravnikom.
The relevance of these data for human exposure is unknown as these effects have been seen as related to well-known pharmacodynamic or species-specific actions.
Pomembnost teh podatkov za uporabo pri človeku ni znana, saj so ugotovili, da so ti učinki povezani z dobro znano farmakodinamiko ali delovanjem, značilnim za posamezne vrste.